Recent advances in immunotherapy for non-small-cell lung cancer.

摘要: Despite of recent development in the field molecular targeted therapies, lung cancer is a leading cause death world. Remarkable progress has been made recently immunotherapy for patients with non-small-cell (NSCLC), several modalities, concepts, and treatment settings being investigated. In vaccine development, large-scale clinical trials such as those L-BLP25, belagenpumatucel-L, TG4010, talactoferrin are already ongoing some results have reported. A trial adjuvant therapy completely resected NSCLC also one major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. More recently, effectiveness multiple peptide vaccines shown. Recently developed unique modalities immune checkpoint inhibitors, antibodies against PD-1 PD-L1, which show promise. However, although therapeutic generally thought to be safe, severe adverse events should monitored carefully when using inhibitors. Here, we discuss advances future perspectives NSCLC.